Literature DB >> 22921484

Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis.

Benjamin C Cheah1, Cindy S Y Lin, Susanna B Park, Steve Vucic, Arun V Krishnan, Matthew C Kiernan.   

Abstract

OBJECTIVE: To elucidate longitudinal changes in axonal function in amyotrophic lateral sclerosis (ALS) patients, and to relate such changes with motor unit loss and functional impairment.
METHODS: 37 ALS patients (age, 53.7 ± 1.7 years; 22 males) were studied using axonal excitability techniques at baseline and 12 weeks follow-up.
RESULTS: Longitudinal measurements across excitability parameters suggested increasing K(+) channel dysfunction, with further increases in depolarising threshold electrotonus (90-100 ms, baseline, 46.8 ± 1.0%; follow-up, 48.7 ± 0.8%; P=0.02) and superexcitability (baseline, -24.0 ± 1.2%; 12 weeks, -26.0 ± 1.2%; P=0.04). Patients with preserved compound muscle action potential (CMAP) amplitude at follow-up developed more severe changes in axonal excitability than those in whom CMAP decreased from baseline, suggesting that the most pronounced disease effects were on motor axons immediately prior to axonal loss in ALS patients. Fine motor decline was associated with more severe changes in axonal excitability, suggesting that functional impairment was related to axonal dysfunction.
CONCLUSIONS: Longitudinal changes in axonal excitability in ALS patients suggest increasing K(+) channel dysfunction in motor axons. SIGNIFICANCE: Axonal excitability studies enable investigation of longitudinal changes in axonal ion channel dysfunction, and thereby the processes that potentially contribute to axonal degeneration in ALS.
Copyright © 2012 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921484     DOI: 10.1016/j.clinph.2012.06.020

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  10 in total

Review 1.  Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS.

Authors:  Susanna B Park; Matthew C Kiernan; Steve Vucic
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

2.  In vivo evidence for reduced ion channel expression in motor axons of patients with amyotrophic lateral sclerosis.

Authors:  James Howells; José Manuel Matamala; Susanna B Park; Nidhi Garg; Steve Vucic; Hugh Bostock; David Burke; Matthew C Kiernan
Journal:  J Physiol       Date:  2018-10-17       Impact factor: 5.182

3.  The puzzling case of hyperexcitability in amyotrophic lateral sclerosis.

Authors:  Jong Seok Bae; Neil G Simon; Parvathi Menon; Steve Vucic; Matthew C Kiernan
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

4.  Ion channel dysfunction and altered motoneuron excitability in ALS.

Authors:  Eric LoRusso; James J Hickman; Xiufang Guo
Journal:  Neurol Disord Epilepsy J       Date:  2019-07-30

Review 5.  New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis.

Authors:  Xueping Chen; Hui-Fang Shang
Journal:  Transl Neurodegener       Date:  2015-09-30       Impact factor: 8.014

6.  Axonal Dysfunction Precedes Motor Neuronal Death in Amyotrophic Lateral Sclerosis.

Authors:  Yuta Iwai; Kazumoto Shibuya; Sonoko Misawa; Yukari Sekiguchi; Keisuke Watanabe; Hiroshi Amino; Satoshi Kuwabara
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

7.  Assessing neuraxial microstructural changes in a transgenic mouse model of early stage Amyotrophic Lateral Sclerosis by ultra-high field MRI and diffusion tensor metrics.

Authors:  Rodolfo G Gatto; Carina Weissmann; Manish Amin; Ariel Finkielsztein; Ronen Sumagin; Thomas H Mareci; Osvaldo D Uchitel; Richard L Magin
Journal:  Animal Model Exp Med       Date:  2020-04-16

8.  Shorter axon initial segments do not cause repetitive firing impairments in the adult presymptomatic G127X SOD-1 Amyotrophic Lateral Sclerosis mouse.

Authors:  V S Bonnevie; K P Dimintiyanova; A Hedegaard; J Lehnhoff; L Grøndahl; M Moldovan; C F Meehan
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

Review 9.  Quantifying disease progression in amyotrophic lateral sclerosis.

Authors:  Neil G Simon; Martin R Turner; Steve Vucic; Ammar Al-Chalabi; Jeremy Shefner; Catherine Lomen-Hoerth; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2014-09-30       Impact factor: 10.422

10.  Do We Have a Channel Solution for ALS?

Authors:  Mamede de Carvalho
Journal:  EBioMedicine       Date:  2015-12-03       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.